Cited by 479Multiple Sclerosis Research StudiesAnimal testing and alternativesPeripheral Neuropathies and Disorders

The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.

How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis.

Steinman, Lawrence, Zamvil, Scott S.·2006·Annals of Neurology

DOI 10.1002/ana.20913

Open this paper in CoChat — free account

Abstract

In their Point of View entitled "Experimental Allergic Encephalomyelitis: A Misleading Model of Multiple Sclerosis," Sriram and Steiner(1) wrote, "The most disappointing aspect of EAE [experimental allergic encephalomyelitis] as a potential model for MS is its almost total inability to point toward a meaningful therapy or therapeutic approach for MS." Actually, EAE has led directly to the development of three therapies approved for use in multiple sclerosis (MS): glatiramer acetate, mitoxantrone, and natalizumab. Several new approaches to MS are in clinical trials based on positive indications in preclinical work relying on EAE. New clues to the pathogenesis of MS and new potential surrogate markers for MS are shown from research involving EAE when it is critically coupled with actual findings in MS. There are pitfalls in overreliance on the EAE model, or on any animal model for any human disease. Nevertheless, over the past 73 years, the EAE model has proved itself remarkably useful for aiding research on MS.

Integrity signals

Registry

Crossref · 10.1002/ana.20913

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdová, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., LUBLIN, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,433
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Yednock, T. A., Cannon, C., Fritz, L. C., Sánchez‐Madrid, F., Steinman, L., & Karin, N. (1992) · Nature · doi:10.1038/356063a0 · Cited by 1,737
Self-citation
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
Johnson, K., Brooks, B., Cohen, J. A., Ford, C., Goldstein, J., Lisak, R., Myers, L., Panitch, H., Rose, J., Schiffer, R., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,667
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis
Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E. E., Garren, H., Langer-Gould, A. M., Strober, S., Cannella, B., Allard, J. D., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-500 · Cited by 1,659
Self-citation
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors
Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E. E., Baumruker, T., HIESTAND, P. C., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200176200 · Cited by 1,512
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E. W., LUBLIN, F. D., Weinstock‐Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,342
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
Youssef, S., Stüve, O., Patarroyo, J. C., Ruiz, P. J., Radosevich, J. L., Hur, E. M., Bravo, M., Mitchell, D. J., Sobel, R. A., Steinman, L., et al. (2002) · Nature · doi:10.1038/nature01158 · Cited by 1,096
Self-citation
TNF neutralization in MS
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) · Neurology · doi:10.1212/wnl.53.3.457 · Cited by 1,068
The T Lymphocyte In Experimental Allergic Encephalomyelitis
Zamvil, S. S., & Steinman, L. (1990) · Annual Review of Immunology · doi:10.1146/annurev.iy.08.040190.003051 · Cited by 1,013
Self-citation
TNFα promotes proliferation of oligodendrocyte progenitors and remyelination
Arnett, H. A., Mason, J., Marino, M., Suzuki, K., Matsushima, G. K., & Ting, J. P.-Y. (2001) · Nature Neuroscience · doi:10.1038/nn738 · Cited by 1,012
Identification of autoantibodies associated with myelin damage in multiple sclerosis
Genain, C. P., Cannella, B., Hauser, S. L., & Raine, C. S. (1999) · Nature Medicine · doi:10.1038/5532 · Cited by 891
The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease
Chabas, D., Baranzini, S. E., Mitchell, D., Bernard, C. C. A., Rittling, S. R., Denhardt, D. T., Sobel, R. A., Lock, C., Karpuj, M., Pedotti, R., et al. (2001) · Science · doi:10.1126/science.1062960 · Cited by 829 · cited 14×
“Osteopontin, a cytokine-like molecule, was thus shown to have important immunomodulatory properties in EAE.74 Researchers then explored whether osteopontin might play a role in the progression of MS.”
BackgroundInfluentialSelf-citation
Myelin Oligodendrocyte Glycoprotein–specific T Cell Receptor Transgenic Mice Develop Spontaneous Autoimmune Optic Neuritis
Bettelli, E., Pagany, M., Weiner, H. L., Linington, C., Sobel, R. A., & Kuchroo, V. K. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021603 · Cited by 828
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
Bielekova, B., Goodwin, B. L., Richert, N. D., Cortese, I. C. M., Kondo, T., Afshar, G., Gran, B., Eaton, J. K., Antel, J. P., Frank, J. A., et al. (2000) · Nature Medicine · doi:10.1038/80516 · Cited by 823
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
van Oosten, B. W., Barkhof, F., Truyen, L., Boringa, J., Bertelsmann, F. W., Blomberg, B. M. E. V., Woody, J. N., Hartung, H., & Polman, C. H. (1996) · Neurology · doi:10.1212/wnl.47.6.1531 · Cited by 735
THE INFLUENCE OF THE PROINFLAMMATORY CYTOKINE, OSTEOPONTIN, ON AUTOIMMUNE DEMYELINATING DISEASE
Chabas, D., Baranzini, S. E., Mitchell, D. J., Bernard, C. C. A., Rittling, S. R., Denhardt, D. T., Sobel, R. A., Lock, C., Karpuj, M. V., Pedotti, R., et al. (2002) · International Conference on Osteopontin and SIBLING Proteins · doi:10.1100/tsw.2002.326 · Cited by 729
Self-citation
Statin therapy and autoimmune disease: from protein prenylation to immunomodulation
Greenwood, J., Steinman, L., & Zamvil, S. S. (2006) · Nature reviews. Immunology · doi:10.1038/nri1839 · Cited by 696
Self-citation
An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis.
Ruddle, N. H., Bergman, C. M., McGrath, K. M., Lingenheld, E. G., Grunnet, M. L., Padula, S. J., & Clark, R. B. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.172.4.1193 · Cited by 689
OBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS
Rivers, T. M., Sprunt, D. H., & Berry, G. P. (1933) · Journal of Experimental Medicine · doi:10.1084/jem.58.1.39 · Cited by 643
TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination
Liu, J., Marino, M. W., Wong, G., Grail, D., Dunn, A. R., Bettadapura, J., Slavin, A., Old, L. J., & Bernard, C. C. A. (1998) · Nature Medicine · doi:10.1038/nm0198-078 · Cited by 548
T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination
Zamvil, S. S., Nelson, P. A., Trotter, J., Mitchell, D. J., Knobler, R., Fritz, R. B., & Steinman, L. (1985) · Nature · doi:10.1038/317355a0 · Cited by 532
Self-citation
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
Kappos, L., Comi, G., PANITCH, H. S., Oger, J. J.-F., Antel, J. P., Conlon, P. J., Steinman, L., Comı, G., Kappos, L., Oger, J. J.-F., et al. (2000) · Nature Medicine · doi:10.1038/80525 · Cited by 512
Self-citation
Oral simvastatin treatment in relapsing-remitting multiple sclerosis
Vollmer, T. R., Key, L., Durkalski, V., Tyor, W. R., Corboy, J. R., Markovic‐Plese, S., Preiningerova, J. L., Rizzo, M., & Singh, I. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16205-3 · Cited by 471
A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple Sclerosis
Bornstein, M. B., Miller, A., Slagle, S., Weitzman, M., Crystal, H., Drexler, E. D., Keilson, M. J., Merriam, A. E., Wassertheil-Smoller, S. W., Spada, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708133170703 · Cited by 462
Anti—tumor necrosis factor therapy abrogates autoimmune demyelination
Selmaj, K. W., Raine, C. S., & Cross, A. H. (1991) · Annals of Neurology · doi:10.1002/ana.410300510 · Cited by 441
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide
Teitelbaum, D., Meshorer, A., Hirshfeld, T., Arnon, R., & Sela, M. (1971) · European Journal of Immunology · doi:10.1002/eji.1830010406 · Cited by 433
Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis
Duda, P. W., Schmied, M. C., Cook, S. L., Krieger, J. I., & Hafler, D. A. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8970 · Cited by 416
GENETIC CONTROL OF THE ANTIBODY RESPONSE
McDevitt, H. O., & Sela, M. (1965) · The Journal of Experimental Medicine · doi:10.1084/jem.122.3.517 · Cited by 404
Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein
Brocke, S., Gijbels, K., Allegretta, M., Ferber, I., Piercy, C., Blankensteini, T., Martinꝉ, R., Utz, U., Karin, N., Mitchell, D. J., et al. (1996) · Nature · doi:10.1038/379343a0 · Cited by 371
Self-citation
A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor
Madsen, L. S., Andersson, E. C., Jansson, L., Krogsgaard, M., Andersen, C. B., Engberg, J., Strominger, J. L., Svejgaard, A., Hjorth, J. P., Holmdahl, R., et al. (1999) · Nature Genetics · doi:10.1038/15525 · Cited by 335
Uncoupling the Proinflammatory from the Immunosuppressive Properties of Tumor Necrosis Factor (Tnf) at the P55 TNF Receptor Level
Kassiotis, G., & Kollias, G. A. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.4.427 · Cited by 332
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab
Steinman, L. (2005) · Nature reviews. Drug discovery · doi:10.1038/nrd1752 · Cited by 328
Self-citation
Lipid microarrays identify key mediators of autoimmune brain inflammation
Kanter, J. L., Narayana, S., Ho, P. P.-K., Catz, I., Warren, K. G., Sobel, R. A., Steinman, L., & Robinson, W. H. (2005) · Nature Medicine · doi:10.1038/nm1344 · Cited by 317
Self-citation
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β
Bielekova, B., Richert, N. D., Howard, T., Blevins, G., Markovic‐Plese, S., McCartin, J., Wuerfel, J. T., Ohayon, J. M., Waldmann, T. A., McFarland, H. F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402653101 · Cited by 314
Design of effective immunotherapy for human autoimmunity
Feldmann, M., & Steinman, L. (2005) · Nature · doi:10.1038/nature03727 · Cited by 283
Self-citation
Experimental allergic encephalomyelitis: A misleading model of multiple sclerosis
Sriram, S., & Steiner, I. (2005) · Annals of Neurology · doi:10.1002/ana.20743 · Cited by 265
Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.
Fridkis‐Hareli, M., Teitelbaum, D., Gurevich, E. P., Pecht, I., Brautbar, C., Kwon, O.-J., Brenner, T., Arnon, R., & Sela, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4872 · Cited by 243
Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor‐immunoglobulin fusion proteins
Baker, D., Butler, D. M., Scallon, B. J., O'Neill, J. K., Turk, J. L., & Feldmann, M. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240916 · Cited by 230
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
Polman, C. H., Barkhof, F., Sandberg‐Wollheim, M., Linde, A., Nordle, Ö., & Nederman, T. (2005) · Neurology · doi:10.1212/01.wnl.0000154520.48391.69 · Cited by 227
Lovastatin inhibits brain endothelial cell Rho‐mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis
Greenwood, J., Walters, C. E., Pryce, G., Kanuga, N., Bemud, E., Baker, D., & Adamson, P. (2003) · The FASEB Journal · doi:10.1096/fj.02-1014fje · Cited by 227
Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production.
Karin, N., Mitchell, D. J., Brocke, S., LING, N. C., & Steinman, L. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.6.2227 · Cited by 211
Self-citation
Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications
Arnon, R., & Aharoni, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404887101 · Cited by 205
An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide
Pedotti, R., Mitchell, D., Wedemeyer, J., Karpuj, M., Chabas, D., Hattab, E., Tsai, M., Galli, S., & Steinman, L. (2001) · Nature Immunology · doi:10.1038/85266 · Cited by 198
Self-citation
Relapsing experimental allergic encephalomyelitis in the SJL/J mouse.
Brown, A. M., & McFarlin, D. E. (1981) · PubMed · Cited by 196
Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis
Angelov, D. N., Waibel, S., Guntinas‐Lichius, O., Lenzen, M., Neiss, W. F., Tomov, T. L., Yoles, E., Kipnis, J., Schori, H., Reuter, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530191100 · Cited by 193
Plasma osteopontin levels in multiple sclerosis.
Comabella, M., Pericot, I., Goertsches, R., Nos, C., Castillo, M., Navarro, J. B., Río, J., & Montalbán, X. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.09.004 · Cited by 184
Apoptosis of Oligodendrocytes via Fas and TNF-R1 Is a Key Event in the Induction of Experimental Autoimmune Encephalomyelitis
Hövelmeyer, N., Hao, Z., Kranidioti, K., Kassiotis, G., Buch, T., Frommer, F., von Hoch, L., Krämer, D., Minichiello, L., Kollias, G. A., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5875 · Cited by 169
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis
Brunmark, C., Runström, A., Ohlsson, L., Sparre, B., Brodin, T., Åström, M., & Hedlund, G. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00225-4 · Cited by 164
Treatment of multiple sclerosis with an anti–interleukin‐2 receptor monoclonal antibody
ROSE, J. W., Watt, H. E., White, A. T., & Carlson, N. G. (2004) · Annals of Neurology · doi:10.1002/ana.20287 · Cited by 163
Clinical Stabilization and Effective B-Lymphocyte Depletion in the Cerebrospinal Fluid and Peripheral Blood of a Patient With Fulminant Relapsing-Remitting Multiple Sclerosis
Stüve, O., Cepok, S., Elias, B., Saleh, A., Hartung, H.-P., Hemmer, B., & Kieseier, B. C. (2005) · Archives of Neurology · doi:10.1001/archneur.62.10.1620 · Cited by 149
Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis
Yu, M., Nishiyama, A., Trapp, B. D., & Tuohy, V. K. (1996) · Journal of Neuroimmunology · doi:10.1016/0165-5728(95)00160-3 · Cited by 147
Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis
Stanislaus, R., Singh, A. K., & Singh, I. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1207 · Cited by 140
Transcriptional analysis of targets in multiple sclerosis
Steinman, L., & Zamvil, S. (2003) · Nature reviews. Immunology · doi:10.1038/nri1108 · Cited by 135
Self-citation
Elevated osteopontin levels in active relapsing‐remitting multiple sclerosis
Vogt, M., Lopatinskaya, L., Smits, M., Polman, C., & Nagelkerken, L. (2003) · Annals of Neurology · doi:10.1002/ana.10606 · Cited by 131
Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer
Teitelbaum, D., Webb, C., Bree, M. M., Meshorer, A., Arnon, R., & Sela, M. (1974) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(74)90012-9 · Cited by 126
Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen
Teitelbaum, D., Webb, C., Meshorer, A., Arnon, R., & Sela, M. (1973) · European Journal of Immunology · doi:10.1002/eji.1830030505 · Cited by 122
Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms
Gaur, A., Boehme, S. A., Chalmers, D. T., Crowe, P. D., Pahuja, A., LING, N. C., Brocke, S., Steinman, L., & Conlon, P. J. (1997) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(96)00220-2 · Cited by 118
Self-citation
Promiscuous Binding of Synthetic Copolymer 1 to Purified HLA-DR Molecules
Fridkis‐Hareli, M., & Strominger, J. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4386 · Cited by 111
Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity
Stüve, O. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25805 · Cited by 107
Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features.
Warren, K. G., Catz, I., & Steinman, L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.11061 · Cited by 106
Self-citation
Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis
Pomeroy, I. M., Matthews, P. M., Frank, J. A., Jordan, E. K., & Esiri, M. M. (2005) · Brain · doi:10.1093/brain/awh626 · Cited by 102
Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87–99)
Vergelli, M., Hemmer, B., Utz, U., Vogt, A. B., Kalbus, M., Tranquill, L. R., Conlon, P. J., LING, N. C., Steinman, L., McFarland, H. F., et al. (1996) · European Journal of Immunology · doi:10.1002/eji.1830261113 · Cited by 95
Self-citation
Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients.
Vogt, M., Floris, S., Killestein, J., Knol, D. L., Smits, M., Barkhof, F., Polman, C., & Nagelkerken, L. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.06.007 · Cited by 94
Suppression of experimental allergic encephalomyelitis by mitoxantrone
Ridge, S. C., Sloboda, A. E., McReynolds, R. A., Levine, S., Oronsky, A. L., & Kerwar, S. S. (1985) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(85)90075-3 · Cited by 94
Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis
Abramsky, O., Teitelbaum, D., & Arnon, R. (1977) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(77)90220-9 · Cited by 93
Some Misconceptions about Understanding Autoimmunity through Experiments with Knockouts
Steinman, L. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.12.2039 · Cited by 91
Self-citation
Delayed, relapsing experimental allergic encephalomyelitis in mice.
LUBLIN, F. D., Maurer, P. H., Berry, R. G., & Tippett, D. S. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.126.3.819 · Cited by 87
Identification of T cell subsets and B lymphocytes in mouse brain experimental allergic encephalitis lesions.
Sriram, S., Solomon, D., Rouse, R. V., & Steinman, L. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.129.4.1649 · Cited by 86
Self-citation
Experimental allergic encephalomyelitis in the New World monkey Callithrix jacchus
Genain, C. P., & Hauser, S. L. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1830113.x · Cited by 85
High Incidence of Spontaneous Disease in an HLA-DR15 and TCR Transgenic Multiple Sclerosis Model1
Ellmerich, S., Mycko, M., Takács, K., Waldner, H., Wahid, F., Boyton, R., King, R., Smith, P. A., Amor, S., Herlihy, A., et al. (2005) · Journal of Immunology · doi:10.4049/jimmunol.174.4.1938 · Cited by 83
Genetics of multiple sclerosis
Oksenberg, J. R., & Hauser, S. L. (2005) · Neurologic Clinics · doi:10.1016/j.ncl.2004.09.006 · Cited by 81
Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone
LUBLIN, F. D., Lavasa, M., Viti, C., & Knobler, R. L. (1987) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(87)90118-8 · Cited by 76
Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis
Menge, T., Lalive, P. H., von Büdingen, H. ‐., Cree, B., Hauser, S. L., & Genain, C. P. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.03.023 · Cited by 70
Optic Neuritis, A New Variant of Experimental Encephalomyelitis, A Durable Model for All Seasons, Now In Its Seventieth Year
Steinman, L. (2003) · Journal of Experimental Medicine · doi:10.1084/jem.20030320 · Cited by 60
Self-citation
The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs
Keith, A. B., Arnon, R., Teitelbaum, D., CASPARY, E. A., & Wisniewski, H. M. (1979) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(79)90058-3 · Cited by 57
A review of systemic nonspecific immunosuppressive treatment of multiple sclerosis
Ellison, G. W., & Myers, L. W. (1978) · Neurology · doi:10.1212/wnl.28.9_part_2.132 · Cited by 52
Selective Treatment of Multiple Sclerosis
Ropper, A. H. (2006) · New England Journal of Medicine · doi:10.1056/nejme068002 · Cited by 47
Autoimmune effector cells. IX. Inhibition of adoptive transfer of autoimmune encephalomyelitis with a monoclonal antibody specific for interleukin 2 receptors.
Hayosh, N. S., & Swanborg, R. H. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.11.3771 · Cited by 37
Protection against Experimental Allergic Encephalomyelitis
Teitelbaum, D., Webb, C., Meshorer, A., Arnon, R., & Sela, M. (1972) · Nature · doi:10.1038/240564b0 · Cited by 37
Therapeutic Effect of the Immunomodulator Glatiramer Acetate on Trinitrobenzene Sulfonic Acid-Induced Experimental Colitis
Aharoni, R., Kayhan, B., & Arnon, R. (2005) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200502000-00003 · Cited by 32
Genomic and proteomic analysis of multiple sclerosis. Opinion.
Robinson, W., Utz, P., & Steinman, L. (2003) · Current Opinion in Immunology · doi:10.1016/j.coi.2003.09.015 · Cited by 30
Self-citation
The Concept of Specific Immune Treatment Against Autoimmune Diseases
Sela, M. (1999) · International Reviews of Immunology · doi:10.3109/08830189909043025 · Cited by 19
Immunomodulatory Vaccines Against Autoimmune Diseases
Sela, M. (2006) · Rejuvenation Research · doi:10.1089/rej.2006.9.126 · Cited by 18
Immunomodulation of Experimental Autoimmune Encephalomyelitis with Ordered Peptides Based on MHC-TCR Binding Motifs
Ruiz, P. J., DeVoss, J., Nguyen, L.-V. T., da Fontoura, P. P., Hirschberg, D. L., Mitchell, D. J., García, K. C., & Steinman, L. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2688 · Cited by 15
Self-citation
Restrictive and diversifying elements of the anti-myelin/oligodendrocyte glycoprotein antibody response in primate experimental allergic encephalomyelitis
von Büdingen, H. ‐., Menge, T., Hauser, S. L., & Genain, C. P. (2006) · Immunogenetics · doi:10.1007/s00251-006-0100-y · Cited by 9
Therapeutic approaches to secondary progressive multiple sclerosis
Lublin, F. D. (2002) · Multiple Sclerosis Journal · doi:10.1177/135245850200800119 · Cited by 4
MRI aspects of secondary progressive multiple sclerosis
Wolinsky, J. S. (2002) · Multiple Sclerosis Journal · doi:10.1177/135245850200800118 · Cited by 4

Sorted by citations

Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles’ Physicochemical Properties on Responses in Biological Systems
Yusuf, A., Almotairy, A. R. Z., Henidi, H. A., Alshehri, O. Y., & Aldughaim, M. S. (2023) · Polymers · doi:10.3390/polym15071596 · Cited by 1,008
The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration
Hauser, S. L., & Oksenberg, J. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.011 · Cited by 793
Myelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes‐Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 799

See all 479

Authors: Steinman, L., & Zamvil, S. S.
Affiliations: Stanford University (US)
University of California, San Francisco (US)
Corresponding author: Steinman, Lawrence
ORCID: Steinman, Lawrence
Zamvil, Scott S.
Venue: Annals of Neurology
Publisher: Wiley
Published: 2006-06-26
Volume: 60
Issue: 1
Pages: 12-21
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.20913
OpenAlex: W2140830894
Cited by: 479
References: 88
Citations by year: 2026: 5 · 2025: 6 · 2024: 6 · 2023: 9 · 2022: 23 · 2021: 18 · 2020: 17 · 2019: 17 · 2018: 13 · 2017: 19 · 2016: 22 · 2015: 23 · 2014: 29 · 2013: 44 · 2012: 37
FWCI: 5.49
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Annals of Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: Multiple Sclerosis Society
National Institute of Allergy and Infectious Diseases (R01AI059709)
Topics: Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
Keywords: experimental autoimmune encephalomyelitis, multiple sclerosis, animal models of disease, translational research, glatiramer acetate, mitoxantrone, natalizumab, MS pathogenesis, surrogate markers, preclinical drug development
MeSH terms: Animals, Disease Models, Animal, Encephalomyelitis, Autoimmune, Experimental, Humans, Multiple Sclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks